Healthcare Industry

According to our new research study on the sector called “Booming Clinical Trials Market in India”, the clinical trial outsourced market in India is forecasted to grow at a CAGR of around 31% during 2010-2012. Presently, the market is characterized by the dominance of phase III and phase II trials, which currently hold more than 80% of the market.

  • In August 2005, the top 12 pharmaceutical companies reported performing 175 ongoing trials in Germany and 161 in the United Kingdom, but only 26 in India, 24 in China, and five in Russia.
  • For example, depending on the choice of location, cost savings can range from 30 to 65 percent compared with sites in the United States or Western Europe.
  • States so when one country approves a drug, the other will clear it at the same time.
  • Pfizer doubled its clinical research investment in India to roughly $13 million and plans to invest another $30 million there over the next five years. Of course, this is a tiny fraction of Pfizer's total global R&D spend of $8 billion, but the growing optimism for this market is clear.
  • Pfizer doubled its clinical research investment in India to roughly $13 million and plans to invest another $30 million there over the next five years. Of course, this is a tiny fraction of Pfizer's total global R&D spend of $8 billion, but the growing optimism for this market is clear.
  • In 2008, pharma market in E7 countries (Brazil, Russia, China, India, Turkey, Mexico and Indonesia) was estimated at around US$ 96 Billion, and it is expected that high growth in these markets will help these countries increase their share in global pharma market.
  • The same is projected to grow at a CAGR of around 14.7% during 2009-2012.
  • MS Health has recently reviewed its previous forecast and stated that the global pharmaceutical market would grow between 4% and 6% to reach a value of $825 Billion in 2010, as reported by PHARMEXEC.
  • The US represents the world’s largest healthcare market, with an annual spending of around US$ 2.24 Trillion in 2007.
  • Healthcare, which is a US$ 35 billion industry in India, is expected to reach over US$ 75 billion by 2012 and US$ 150 billion by 2017, according to Technopak Advisors in their report – ‘India Healthcare Trends 2008’.
  • In the fiscal year 2007-08, India registered a total pharmaceutical turnover of over US$15 Billion.
  • Healthcare industry accounted for 5.1 per cent of the country‘s GDP in 2006 and 6.0 in 2009 start.
  • India's healthcare industry registered 42.44 per cent growth in net profit during April-June 2009, according to the Associated Chambers of Commerce and Industry (ASSOCHAM).
  • The government, along with participation from the private sector, is planning to invest US$ 1 billion to US$ 2 billion in an effort to make India one of the top five global pharmaceutical innovation hubs by 2020.
  • The Government launched the National Rural Health Mission (NRHM) in 2005. It aims to provide quality healthcare for all and increase the expenditure on healthcare from 0.9 per cent of GDP to 2-3 per cent of GDP by 2012